CAMBRIDGE, Mass., Dec. 22, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced it has completed the sale of an additional 218,647 shares of its common stock to the underwriters in connection with the previously announced underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $14.35 per share. UBS Investment Bank was the sole book-running manager for the offering. Cowen and Company and Canaccord Genuity acted as co-managers for the offering. The underwriters exercised their option to purchase the additional shares of common stock to cover over-allotments. The aggregate net proceeds to Momenta from the initial closing on December 13, 2010 and the over-allotment closing, after deducting customary underwriting discounts and commissions, were approximately $57.2 million.
